top of page
about us

Silencing Diseases With RNAi


RNA interference (RNAi) is a conserved natural defence mechanism against exogenous nucleic acids, brought about by RNAi triggers, including short interfering RNAs or siRNAs.


The discovery of RNAi was awarded the 2006 Nobel Prize for Physiology or Medicine and sparked the development of innovations which harnesses this mechanism to silence disease causing RNA.


RNAi is widely accepted as a feasible treatment modality for certain diseases where the disease causing nucleic acid/protein is not druggable by small molecules or biologics.

Cargene creates nucleic acid (including siRNA)–based drugs which are delivered to target organs by specially conjugated ligands.

Our Platforms

Discovery screenshot .png

Our proprietary platforms efficiently generate highly potent, stable and safe oligonucleotides to treat a broad range of diseases.

Image for 1st in class_4.jpg

Our First-In-Class Liver Regeneration Program


Our breakthrough in vivo functional genomics platform developed by our Scientific Co-Founder Torsten Wuestefeld uncovers novel targets for Liver Regeneration.


siRNA is the best modality to capitalize on our first-in-class targets to accelerate the path to clinic.


Silencing these novel targets attenuate liver fibrosis and enhance hepatocyte regeneration in multiple models.

Our Pipeline

Our drug development pipeline consists of therapeutic candidates for a strategic set of clinical indications.
In addition, we have established a first-in-class liver regeneration program with multiple targets to resolve fibrosis

Pipeline Image 03Jan2023.jpg
bottom of page